BRIEF published on 08/11/2026 at 18:35, 1 day 15 hours ago Medincell at Piper Sandler CNS Symposium 2026 Investors Medincell BEPO Technology Piper Sandler CNS Symposium Prolonged Treatments
BRIEF published on 08/11/2026 at 18:35, 1 day 15 hours ago Medincell au Piper Sandler CNS Symposium 2026 Investisseurs Medincell Piper Sandler CNS Symposium BEPO Technologie Traitements Prolongés
PRESS RELEASE published on 08/11/2026 at 18:30, 1 day 16 hours ago Informations privilégiées / Autres communiqués Medincell participera au Piper Sandler CNS Symposium le 13 août 2026 avec le Dr Grace Kim, CSO, U.S. Finance. L'entreprise développe des traitements injectables à action prolongée pour divers domaines thérapeutiques Medincell Dr Grace Kim Action Prolongée Piper Sandler CNS Symposium Traitements Injectables
BRIEF published on 07/29/2026 at 13:29, 14 days 21 hours ago Medincell Partner Teva Reports Strong UZEDY® Sales Growth Net Sales Growth Revenue Outlook Schizophrenia Treatment Teva Pharmaceuticals Long-acting Injectable
BRIEF published on 07/29/2026 at 13:29, 14 days 21 hours ago Record sales for UZEDY® in the second quarter of 2026 Schizophrenia Teva Pharmaceuticals UZEDY Sales 2026 Forecast Medincell Royalties
BRIEF published on 07/29/2026 at 13:29, 14 days 21 hours ago Ventes record pour UZEDY® au deuxième trimestre 2026 Schizophrénie Teva Pharmaceuticals Ventes UZEDY Prévisions 2026 Royalties Medincell
BRIEF published on 07/29/2026 at 13:29, 14 days 21 hours ago Le partenaire de Medincell, Teva, annonce une forte croissance des ventes d'UZEDY® Croissance Des Ventes Nettes Traitement De La Schizophrénie Perspectives De Revenus Teva Pharmaceuticals Injectable À Action Prolongée
PRESS RELEASE published on 07/29/2026 at 13:24, 14 days 21 hours ago Inside Information / Other news releases Teva's UZEDY® achieves record Q2 net sales of $77M, up 43% YoY. Olanzapine LAI FDA action anticipated in Q4 2026. Medincell's innovative long-acting injectable treatments show promising results Record Sales Medincell Teva UZEDY Long-acting Injectable
PRESS RELEASE published on 07/29/2026 at 13:24, 14 days 21 hours ago Informations privilégiées / Autres communiqués Ventes record d'UZEDY® de 77 M$ au 2ème trimestre 2026 (+43% sur un an), Teva relève ses prévisions. Annonce sur les résultats de Teva : ir.tevapharm.com Schizophrénie Ventes Record Teva Pharmaceuticals UZEDY® Prévisions 2026
BRIEF published on 07/28/2026 at 20:26, 15 days 14 hours ago Publication of the 2025/2026 Universal Registration Document by Medincell Financial Report General Assembly CSR Registration Document Medincell
Published on 08/13/2026 at 09:05, 1 hour 29 minutes ago Battery X Metals Appoints Lithium-Ion Battery and Electric Vehicle Entrepreneur William Fan as President to Advance Development of Its Patent-Pending Lithium-Ion Battery Rebalancing Technology Platform and Corporate Growth Initiatives
Published on 08/13/2026 at 08:00, 2 hours 34 minutes ago Battery X Metals Maintains Y Lithium Project Claims in Good Standing and Evaluates Phase I Exploration Program
Published on 08/13/2026 at 07:30, 3 hours 4 minutes ago Battery X Metals Announces Closing of Second Tranche of Private Placement to Advance Corporate Growth Initiatives
Published on 08/12/2026 at 23:30, 11 hours 4 minutes ago CCL Industries Announces Record Results for 2026 Second Quarter
Published on 08/13/2026 at 10:13, 21 minutes ago Turkiye Garanti Bankasi A.S.: Issuance of Green/Sustainable Eurobond
Published on 08/13/2026 at 10:09, 24 minutes ago Turkiye Garanti Bankasi A.S.: Redemption of the debt instrument at abroad within the Medium Term Note (MTN) program
Published on 08/13/2026 at 10:05, 28 minutes ago Thunes Expands Web3 Infrastructure with EURC to Enable Instant Euro Treasury Funding
Published on 08/13/2026 at 10:00, 34 minutes ago BENO Holding AG Acquires and Leases Light Industrial Property in the Nuremberg Metropolitan Area
Published on 08/11/2026 at 17:45, 1 day 16 hours ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 1 day 16 hours ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 2 days 16 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 2 days 16 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
